With typical baseline sexual function, 80 maintained standard sexual function for the duration of remedy.In males with baseline sexual dysfunction, improvement to standard sexual function occurred in 40 of patients inside the placebo, vilazodone 40 mg/day, and citalopram groups; inside the vilazodone 20 mg/day group, 33 of individuals shifted to standard sexual function (Table four). For males with normal baseline sexual function, slightly a lot more citalopram-treated than placebo-treated or vilazodone-treated patients met sexual dysfunction criteria for the duration of treatment.CSFQ domain score modifications by baseline sexual functionIn patients with baseline sexual dysfunction, improvements had been observed on every single CSFQ domain (representing the different phases with the sexual cycle) for guys and ladies in all therapy groups (Table five). In patients with normal sexual function, CSFQ domain scores either minimally improved or decreased for all remedy groups.Adverse events related to sexual functionIn the general security population, spontaneously reported AEs connected to sexual function were slightly more frequent in sufferers within the active-treatment groups than in220 International Clinical Psychopharmacology 2015, Vol 30 NoTableChange in sexual function status during double-blind therapy (CSFQ evaluation population)Sexual function status throughout double-blind treatmentb Sexual dysfunction Normal sexual function Sexual dysfunction Normal sexual function Sexual dysfunction Normal sexual function Sexual dysfunction Standard sexual function Placebo ( ) 72.five 27.5 16.3 83.7 58.eight 41.two 7.three 92.7 Vilazodone 20 mg/day ( ) 66.7 33.3 22.2 77.8 66.7 33.three 10.six 89.four Vilazodone 40 mg/day ( ) 60.7 39.3 18.9 81.1 60.eight 39.2 11.six 88.4 Citalopram 40 mg/day ( ) 72.7 27.3 16.7 83.three 62.0 38.0 17.5 82.Baseline sexual functiona Ladies Sexual dysfunction Typical sexual function Males Sexual dysfunction Normal sexual functionCSFQ, Alterations in Sexual Functioning Questionnaire. Sexual dysfunction at baseline was defined as CSFQ total score 41 (women) or 47(guys) (Clayton et al., 1997). Sexual dysfunction through double-blind therapy period was defined as CSFQ total score 41 (females) or 47 (males) for two consecutive visits for the duration of double-blind treatment.a bTableMean modify from baseline to week ten in CSFQ domain scores (CSFQ analysis population)Placebo Vilazodone 20 mg/day Vilazodone 40 mg/day Citalopram 40 mg/dayCSFQ domain by baseline sexual function status Pleasure Women Sexual dysfunction Regular sexual function Men Sexual dysfunction Standard sexual function Desire/frequency Females Sexual dysfunction Normal sexual function Males Sexual dysfunction Standard sexual function Desire/interest Girls Sexual dysfunction Standard sexual function Men Sexual dysfunction Typical sexual function Arousal Girls Sexual dysfunction Regular sexual function Guys Sexual dysfunction Normal sexual function Orgasm Females Sexual dysfunction Typical sexual function Guys Sexual dysfunction Regular sexual function CSFQ, Alterations in Sexual Functioning Questionnaire.Incensole Acetate Description 0.Silver bis(trifluoromethanesulfonyl)imide Cancer 57 0.PMID:29844565 09 0.87 0.0.56 – 0.18 0.72 0.0.61 0.33 0.43 0.0.31 – 0.20 0.41 0.0.54 – 0.28 0.80 0.0.74 – 0.02 0.54 0.0.76 0.06 0.43 – 0.0.15 – 0.29 0.48 – 0.0.86 0.13 1.50 0.0.81 – 0.41 1.24 0.0.55 – 0.61 0.87 0.0.63 0.41 0.65 0.1.11 – 0.28 1.87 0.1.01 – 0.02 0.92 – 0.1.20 0.15 0.70 – 0.0.80 – 0.12 1.28 0.0.75 – 0.67 1.39 0.0.97 – 0.73 0.48 0.1.21 – 0.58 0.53 – 0.0.21 – 1.00 0.59 – 0.the placebo group, and had been most frequent inside the citalopram group (Table 6), especially for anorgasmia and loss of libido. Incidence of lib.